In the field of antibiotherapy, intracellular infections remain difficult to eradicate mainly due to
the poor intracellular penetration of most of the commonly used antibiotics. Bacteria have …

The continued emergence and spread of drug-resistant pathogens and the decline in the
approval of new antimicrobial drugs pose a major threat to managing infectious diseases …

The percentages of organisms exhibiting antimicrobial resistance, especially resistance to
multiple antibiotics, are incessantly increasing. Studies investigated that many bacteria are …

Abstract Treatment of bacterial airway infections is essential for cystic fibrosis therapy.
However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are …

This study was conducted to evaluate the feasibility of developing inhalable dry powders of
liposomal encapsulated ciprofloxacin nanocrystals (LECN) for controlled drug release. Dry …

Abstract Background and Aims The evidence supported the use of nebulized antibiotics in
non‐cystic fibrosis (non‐CF) bronchiectasis is indefinite. A meta‐analysis was performed to …

Numerous antimicrobial drugs have been developed and commercialized to kill and inhibit
the growth of pathogenic microbes. The therapeutic efficiency of these drugs has however …

Ciprofloxacin is an antibiotic widely used in the treatment of human and animal diseases
and can be found as a contaminant in some foods of animal origin, such as milk. Thus, the …

The airway milieu of individuals with muco-obstructive airway diseases (MADs) is defined by
the accumulation of dehydrated mucus due to hyperabsorption of airway surface liquid and …

Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract
infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease …